Full Press Release Details
Change of Director's
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as
soon as available. Information and documents given to ASX become ASX's property and may be made public.
30/9/2001. Amended 01/01/11
| Name of Entity: | Radiopharm Theranostics Limited (ASX: RAD) |
| ABN: | 57 647 877 889 |
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director: | Ian Turner |
| Date of Last Notice: | 25 February 2025 |
of director's relevant interests in securities
In the case of a trust, this
includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph
(i) of the definition of "notifiable interest of a director" should be disclosed in this part.
| Direct or Indirect Interest | Direct and indirect | |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Superannuation fund | |
| Date of change | 23 May 2025 |
| No. of securities held prior to change | Shares | Options | |||
| Direct | 2,530,595 | 18,167,928 | |||
| Indirect | 3,724,697 | 820,422 | |||
| Total | 6,255,292 | 18,988,350 |
| Number acquired | Shares | Options | |||
| Direct | - | - | |||
| Indirect | 3,000,000 | - | |||
| Total | 3,000,000 | - |
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 1 |
Change of Director's
| Number disposed | Shares | Options | |||
| Direct | - | - | |||
| Indirect | - | - | |||
| Total | - | - |
| No. of securities held after change | Shares | Options | |||
| Direct | 2,530,595 | 18,167,928 | |||
| Indirect | 6,724,697 | 820,422 | |||
| Total | 9,255,292 | 18,988,350 |
Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page 2 | 01/01/2011 |
Change of Director's
Part 3 - Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 3 |